Among the stocks in the Zacks Medical - Drugs industry, Esperion Therapeutics ( ESPR - Free Report ) is soon expected to post loss of $0.14 per share for the quarter ended December 2024. This estimate indicates a year-over-year change of +72%. This quarter's revenue is expected to be $70.01 million, up 117.1% from the year-ago quarter.